Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:2568031.
doi: 10.1155/2016/2568031. Epub 2016 Sep 27.

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation

Affiliations
Review

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation

Nghi C Nguyen et al. Int J Mol Imaging. 2016.

Abstract

Background and Purpose. Radium-223 dichloride (Xofigo®, Bayer HealthCare Pharmaceuticals Inc.) is the first α-particle emitter therapeutic agent approved by the FDA, with benefits in overall survival and delay in symptomatic skeletal event for patients with metastatic castrate-resistant prostate cancer (CRPC). Recent post hoc analyses of the phase III ALSYMPCA trial support the previously established safety profile as well as therapeutic effect and clinical outcome of Radium-223. Currently, Radium-223 is approved as a single agent therapy for metastatic CRPC. Clinical trials are currently investigating Radium-223 in additional clinical settings such as earlier asymptomatic disease and in combination with other agents including hormonal therapeutic agents and immunotherapeutic as well as chemotherapeutic agents. Trials are also ongoing in patients with other primary cancers such as breast cancer, thyroid cancer, and renal cancer metastatic to bone. In this article, the physics and radiobiology, as well as a literature update on the use of Radium-223, are provided along with case presentations, aiming at a better appreciation of research data as well as the assimilation of research data into clinical practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Case #1 of a 71-year-old man. Anterior and posterior bone scan, and CT at baseline (a, b, c), within 3 months after completion of Radium-223 (d, e, f), and 6–12 months after Radium-223 (g, h, i). Imaging findings are summarized in Table 1.
Figure 2
Figure 2
Case #2 of a 65-year-old man. Anterior and posterior bone scan, and CT at baseline (a, b, c), within 3 months after completion of Radium-223 (d, e, f), and 6–12 months after Radium-223 (g, h, i). Imaging findings are summarized in Table 2.
Figure 3
Figure 3
Case #3 of a 67-year-old man. Anterior and posterior bone scan, and CT at baseline (a, b, c) and within 3 months after completion of Radium-223 (d, e, f). Imaging findings are summarized in Table 3.

References

    1. Howlader N., Noone A. M., Krapcho M., et al. SEER Cancer Statistics Review, 1975–2013. Bethesda, Md, USA: National Cancer Institute; based on November 2015 SEER data submission, posted to the SEER web site, 2016.
    1. Roodman G. D. Mechanisms of bone metastasis. The New England Journal of Medicine. 2004;350(16):1655–1664. doi: 10.1056/NEJMra030831. - DOI - PubMed
    1. Parker C., Nilsson S., Heinrich D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine. 2013;369(3):213–223. doi: 10.1056/nejmoa1213755. - DOI - PubMed
    1. Lien L. M. E., Tvedt B., Heinrich D. Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride. International Journal of Urological Nursing. 2015;9(1):3–13. doi: 10.1111/ijun.12059. - DOI - PMC - PubMed
    1. Petrylak D. P., Tangen C. M., Hussain M. H. A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine. 2004;351(15):1513–1520. doi: 10.1056/nejmoa041318. - DOI - PubMed

LinkOut - more resources